{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:20:07Z","timestamp":1789154407904,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS044417"],"award-info":[{"award-number":["R01NS044417"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS052956"],"award-info":[{"award-number":["R01NS052956"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA140408"],"award-info":[{"award-number":["R01CA140408"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA133594"],"award-info":[{"award-number":["R01CA133594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jclinepi.2025.112004","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:34:27Z","timestamp":1759210467000},"page":"112004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Theory of clinical therapeutic progress: reconciling equipoise with fat-tailed (skewed) outcomes"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-5707","authenticated-orcid":false,"given":"Iztok","family":"Hozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2025.112004_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/03605310701255719","article-title":"Articulating and responding to uncertainties in clinical research","volume":"32","author":"Djulbegovic","year":"2007","journal-title":"J Med Philos"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib2","first-page":"71","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human participants","volume":"333","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2025.112004_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0197-2456(80)90006-9","article-title":"Sorting out the doctor's bag","volume":"1","author":"Frederickson","year":"1980","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jclinepi.2025.112004_bib4","series-title":"Philosophy of Medicine (Handbook of the Philosophy of Science)","first-page":"299","article-title":"Uncertainty in clinical medicine","author":"Djulbegovic","year":"2011"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.112004_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/107327480901600409","article-title":"The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research","volume":"16","author":"Djulbegovic","year":"2009","journal-title":"Cancer Control"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112004_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archinte.168.6.632","article-title":"Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the national cancer Institute-sponsored cooperative oncology groups, 1955 to 2006","volume":"168","author":"Djulbegovic","year":"2008","journal-title":"Arch Intern Med"},{"issue":"7463","key":"10.1016\/j.jclinepi.2025.112004_bib7","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/500395a","article-title":"Medical research: trial unpredictability yields predictable therapy gains","volume":"500","author":"Djulbegovic","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jclinepi.2025.112004_bib8","series-title":"Elements of Information Theory","author":"Cover","year":"1991"},{"key":"10.1016\/j.jclinepi.2025.112004_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jclinepi.2022.01.016","article-title":"Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible","volume":"145","author":"Hozo","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-023-02823-9","article-title":"The normality assumption on between-study random effects was questionable in a considerable number of cochrane meta-analyses","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034222","article-title":"Heavy tailed distributions of effect sizes in systematic reviews of complex interventions","volume":"7","author":"Burton","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.112004_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2188\/jea.JE20200376","article-title":"Meta-analysis using flexible random-effects distribution models","volume":"32","author":"Noma","year":"2022","journal-title":"J Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112004_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111828","article-title":"There is no upper limit on the maximum effect that can be detected in randomized trials","volume":"184","author":"Djulbegovic","year":"2025","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib14","doi-asserted-by":"crossref","first-page":"R250","DOI":"10.1186\/ar1170","article-title":"Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development","volume":"6","author":"Fries","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2288-12-85","article-title":"When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt","volume":"12","author":"Djulbegovic","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jclinepi.2025.112004_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1273","article-title":"Rethinking approaches to analysis of global randomised controlled trials","volume":"389","author":"Brophy","year":"2025","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112004_bib17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/aje\/kwx259","article-title":"Invited commentary: the need for cognitive science in methodology","volume":"186","author":"Greenland","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112004_bib18","article-title":"New treatments compared to established treatments in randomized trials","volume":"10","author":"Djulbegovic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058711","article-title":"Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials","volume":"8","author":"Djulbegovic","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2025.112004_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0936-6555(05)80448-0","article-title":"Thirty years of medical research council randomized trials in solid tumours","volume":"9","author":"Machin","year":"1997","journal-title":"Clin Oncol"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112004_bib21","doi-asserted-by":"crossref","first-page":"759","DOI":"10.7326\/M23-2515","article-title":"The benefits and risks of receiving investigational solid tumor drugs in randomized trials: a systematic review and meta-analysis","volume":"177","author":"Iskander","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2025.112004_bib22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1353\/ken.2023.a899457","article-title":"Varieties of community uncertainty and clinical equipoise","volume":"33","author":"London","year":"2023","journal-title":"Kennedy Inst Ethics J"},{"key":"10.1016\/j.jclinepi.2025.112004_bib24","series-title":"An Introduction to Statistical Modeling of Extreme Values","author":"Coles","year":"2001"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112004_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jclinepi.2010.09.007","article-title":"Optimism bias leads to inconclusive results-an empirical study","volume":"64","author":"Djulbegovic","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2025.112004_bib26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1137\/070710111","article-title":"Power-law distributions in empirical data","volume":"51","author":"Clauset","year":"2009","journal-title":"SIAM Rev"},{"key":"10.1016\/j.jclinepi.2025.112004_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/00107510500052444","article-title":"Power laws, pareto distributions and Zipf's law","volume":"46","author":"Newman","year":"2005","journal-title":"Contemp Phys"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.112004_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104555","article-title":"Evolution of treatment regimens in multiple myeloma: a social network analysis","volume":"9","author":"Mahony","year":"2014","journal-title":"PloS one"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001010","article-title":"Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty","volume":"8","author":"Kimmelman","year":"2011","journal-title":"Plos Med"},{"issue":"10092","key":"10.1016\/j.jclinepi.2025.112004_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","article-title":"Progress in evidence-based medicine: a quarter century on","volume":"390","author":"Djulbegovic","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.112004_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jep.13475","article-title":"Research synthesis of information theory measures of uncertainty: meta-analysis of entropy and mutual information of diagnostic tests","volume":"27","author":"Tsalatsanis","year":"2021","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.jclinepi.2025.112004_bib32","series-title":"Some recent contributions to the mathematical theory of communication. Shannon CE, Waever W The mathematical theory of communication","author":"Weaver","year":"1962"},{"key":"10.1016\/j.jclinepi.2025.112004_bib33","series-title":"On Certainty","author":"Wittgenstein","year":"1969"},{"issue":"247","key":"10.1016\/j.jclinepi.2025.112004_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJM195207242470401","article-title":"The clinical trial","author":"Hill","year":"1952","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2025.112004_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jclinepi.2018.01.011","article-title":"Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval","volume":"98","author":"Djulbegovic","year":"2018","journal-title":"J Clin Epidemiol"},{"issue":"10199","key":"10.1016\/j.jclinepi.2025.112004_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0140-6736(19)31128-6","article-title":"The importance of randomised vs non-randomised trials","volume":"394","author":"Djulbegovic","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.112004_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11111","volume":"2","author":"Razavi","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jclinepi.2025.112004_bib38","series-title":"STATA, ver. 18","year":"2022"},{"key":"10.1016\/j.jclinepi.2025.112004_bib39","series-title":"A theory of justice. Revised edition","author":"Rawls","year":"1999"},{"key":"10.1016\/j.jclinepi.2025.112004_bib40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jme.17.1.30","article-title":"At what level of collective equipoise does a clinical trial become ethical?","volume":"17","author":"Johnson","year":"1991","journal-title":"J Med Ethics"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5455\/aim.2013.21.156-159","article-title":"At what level of collective equipoise does a randomized clinical trial become ethical for the members of institutional review board\/ethical committees?","volume":"21","author":"Mhaskar","year":"2013","journal-title":"Acta Inform Med"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.112004_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011150","article-title":"When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members","volume":"6","author":"Mhaskar","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.112004_bib43","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/bimj.201800071","article-title":"When should meta-analysis avoid making hidden normality assumptions?","volume":"60","author":"Jackson","year":"2018","journal-title":"Biometrical J"},{"issue":"Pt 3\u20134","key":"10.1016\/j.jclinepi.2025.112004_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/biomet\/34.3-4.209","article-title":"Testing for normality","volume":"34","author":"Geary","year":"1947","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1037\/0033-2909.105.1.156","article-title":"The unicorn, the normal curve, and other improbable creatures","volume":"105","author":"Micceri","year":"1989","journal-title":"Psychol Bull"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.112004_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtho.2020.10.010","article-title":"Principles and reporting of bayesian trials","volume":"16","author":"Lee","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jclinepi.2025.112004_bib47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bmj.314.7073.74a","article-title":"What is the prior probability of a proposed new treatment being superior to established treatments?","volume":"314","author":"Chalmers","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2025.112004_bib48","series-title":"Modelling Survival Data in Medical Research (3rd ed.)","author":"Collett","year":"2014"},{"key":"10.1016\/j.jclinepi.2025.112004_bib49","series-title":"What is the probability that results of meta-analyses will favor innovative treatments? Presented at","author":"Djulbegovic","year":"2000"},{"issue":"7528","key":"10.1016\/j.jclinepi.2025.112004_bib50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bmj.38628.561123.7C","article-title":"Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the children's oncology group","volume":"331","author":"Kumar","year":"2005","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.112004_bib51","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.293.8.970","article-title":"Evaluation of new treatments in radiation oncology: are they better than standard treatments?","volume":"293","author":"Soares","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2025.112004_bib52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(00)02605-2","article-title":"The uncertainty principle and industry-sponsored research","volume":"356","author":"Djulbegovic","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.112004_bib53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/aje\/kwz261","article-title":"Evaluation of the normality assumption in meta-analyses","volume":"189","author":"Wang","year":"2019","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:50:00Z","timestamp":1780458600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435625003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"alternative-id":["S0895435625003373"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.112004","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theory of clinical therapeutic progress: reconciling equipoise with fat-tailed (skewed) outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.112004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112004"}}